China’s growing life sciences industries, together with its burgeoning economy, represent one of the most exciting market opportunities for biomedical companies – both for MNCs and start-ups alike. China’s rapidly aging population also means a rising demand for innovative healthcare solutions. However, set against the dynamic backdrop of the U.S.-China bilateral relationship, notably the U.S. CFIUS and Export Control expansion, as well as a transitioning policy environment in China, innovators seeking cross-border partnerships and investment opportunities also face substantial challenges. The China Summit @ the BIO International Convention will deliver a robust program featuring keynote presentations as well as panel discussions on noteworthy policies and important trends affecting the global biomedical industry in China. Topics Include: • Recent policy developments on both sides of the Pacific, including market access and reimbursement of innovative biopharmaceuticals in China, as well as the proposed U.S. investment restrictions. • Lessons and opportunities in cross-border partnership and financing, including a year one assessment of the HKEX biotech listing rule. • Silver Lining: An aging China and the implications for healthcare. The event will be conducted in simultaneous interpretation between English and Chinese.